Could a lighter chemo regimen beat standard treatment for HER2+ breast cancer?
NCT ID NCT07421141
First seen Feb 21, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This phase II study tests a de-escalated chemotherapy regimen (paclitaxel, trastuzumab, and pertuzumab, or THP) in 93 patients with early HER2-positive breast cancer, comparing it to a historical control group of 93 patients who received the standard TCHP regimen. The goal is to see if the milder THP combo can achieve similar rates of complete tumor disappearance (pathological complete response) with fewer side effects. If successful, this could lead to a less toxic treatment option for early-stage HER2+ breast cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
P.A. Hertsen Moscow Oncology Research Institute
Moscow, 125284, Russia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paclitaxel, trastuzumab, and pertuzumab (THP)
What this could lead to
If successful, this could offer a less toxic chemotherapy option for early HER2+ breast cancer, reducing side effects while maintaining high cure rates.
What could go wrong
This is a phase II study with only 93 patients on the experimental regimen, and results are compared to a historical control group, which may introduce bias. The milder regimen might not be as effective as the standard treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.